 |
 |  |
As a follow-up to Tuesday's post, management guru Scott Adams shows how promotion by a pharmaceutical manufacturer affects physicians' prescribing decisions.
Of course, this topic may not be funny for much longer given 40,000 recently announced job cuts by Johnson & Johnson, Pfizer, and Astra-Zeneca or the 16,000 cuts planned by Merck.
ADAM J. FEIN, PH.D.Drug Channels is written by Adam J. Fein, Ph.D., founder and president of Pembroke Consulting, Inc.. Dr. Fein, one of the country’s foremost experts on pharmaceutical economics and channel strategy, consults with clients in the pharmaceutical industry. Dr. Fein earned his Ph.D. from the Wharton School of Business and a B.A., summa cum laude, from Brandeis University. He lives in Philadelphia with his wife and their two children.
Investors: Contact the Gerson Lehrman Group to consult with Dr. Fein
1 comments:
To post anonymously, select "Guest" and enter "Anonymous" as your name. Your email will NOT be published.